Express Scripts Formulary Drops Novo Nordisk’s Victoza Based On Lack Of “Added Health Benefit”
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite its patient-friendly once-daily dosing, Novo Nordisk’s market-leading GLP-1 agonist will be dropped from the PBM’s recommended national formulary in 2014. Roughly 35 million individuals are covered by plans that adopt the Express Scripts formulary, of which a subset with type 2 diabetes may be directly impacted by the Victoza change.